Literature DB >> 10553758

Recurrence of neuroleptic malignant syndrome with olanzapine treatment.

S Gheorghiu, H Y Knobler, D Drumer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10553758     DOI： 10.1176/ajp.156.11.1836

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  3 in total

1.  Serum creatine kinase elevation as a possible complication of therapy with olanzapine.

Authors:  Evgeniy Perlov; Ludger Tebartz van Elst; Martin Czygan; Emanuel Bubl; Dieter Ebert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-10-22       Impact factor: 3.000

Review 2.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Olanzapine-associated neuroleptic malignant syndrome: Is there an overlap with the serotonin syndrome?

Authors:  Vassilis P Kontaxakis; Beata J Havaki-Kontaxaki; Nikolaos G Christodoulou; Konstantinos G Paplos; George N Christodoulou
Journal:  Ann Gen Hosp Psychiatry       Date:  2003-10-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.